<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02281422</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-2093-112</org_study_id>
    <nct_id>NCT02281422</nct_id>
  </id_info>
  <brief_title>An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093</brief_title>
  <official_title>An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093 in Subjects With Various Degrees of Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, single-dose (BIA 2-093 800 mg tablet), single-centre study in five groups of
      subjects with various degrees of renal function based on creatinine clearance
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open-label, single-dose (BIA 2-093 800 mg tablet), single-centre study in five
      groups of subjects with various degrees of renal function based on creatinine clearance
      (stages of renal function according to the Food and Drug Administration and the European
      Agency for the Evaluation of Medicinal Products Guidelines) for the evaluation of
      pharmacokinetics in patients with impaired renal function.

      The trial commenced with Groups 1 and 2. An interim safety evaluation was conducted and, as
      there were no safety concerns, the trial continued with Groups 3 and 4. After another interim
      safety evaluation with the data from Groups 3 and 4, the trial commenced with Group 5.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - Peak Plasma Concentration</measure>
    <time_frame>pre-dose and 1, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 5, 7, 9, 12, 24, 48, 72 and 96 hours post-dose.</time_frame>
    <description>BIA 2-194; BIA 2-195; Oxcarbazepine are BIA 2-093 metabolites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-12h) - AUC From Time Zero to 12h</measure>
    <time_frame>pre-dose and 1, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 5, 7, 9, 12, 24, 48, 72 and 96 hours post-dose.</time_frame>
    <description>BIA 2-194; BIA 2-195; Oxcarbazepine are BIA 2-093 metabolites
AUC - area under the plasma concentration versus time curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax (hr) - Time at Which Cmax Occurred</measure>
    <time_frame>pre-dose and 1, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 5, 7, 9, 12, 24, 48, 72 and 96 hours post-dose.</time_frame>
    <description>BIA 2-194; BIA 2-195; Oxcarbazepine are BIA 2-093 metabolites
Cmax - maximum observed plasma drug concentration</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Group 1 normal renal function</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>normal renal function (creatinine clearance &gt; 80 mL/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 mild renal impairment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>mild renal impairment (creatinine clearance 50-80 mL/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 moderate renal impairment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>moderate renal impairment (creatinine clearance 30-50 mL/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 severe renal impairment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>severe renal impairment (creatinine clearance &lt;30 mL/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5 end stage renal disease</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>end stage renal disease, requiring haemodialysis (ESRD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 2-093</intervention_name>
    <arm_group_label>Group 1 normal renal function</arm_group_label>
    <arm_group_label>Group 2 mild renal impairment</arm_group_label>
    <arm_group_label>Group 3 moderate renal impairment</arm_group_label>
    <arm_group_label>Group 4 severe renal impairment</arm_group_label>
    <arm_group_label>Group 5 end stage renal disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females at least 18 years of age, with body mass not less than 50 kg.

          -  Female subjects had to be post-menopausal, surgically sterilized or using a reliable
             method of contraception.

          -  Subjects suffering from a chronic illness, other than hepatic impairment, had to have
             a stable condition, regarded by the investigator as unlikely to influence the outcome
             of the study.

          -  Renal failure, the extent of which, as measured by the creatinine clearance, resulted
             in recruitment to one of five renal function groups.

          -  Medical records indicating a stable serum creatinine (variation of not more than 30%),
             for at least 3 months prior to the screening visit (Groups 2 to 4 only), as determined
             by the clinical investigator. The s√©rum creatinine had to be stable to allow for an
             accurate determination of the creatinine clearance and therefore allowed for correct
             allocation to one of the renal function groups. Subjects who were recruited into Group
             1 had normal renal function.

        Exclusion Criteria:

          -  The receipt of any investigational drug within 30 days prior to this study.

          -  Clinically significant abnormal findings (as judged by the investigator) for the
             following parameters, except those consistent with findings in renal failure:
             haematology, biochemistry, clotting profile, urinalysis, vital signs or ECG screening
             tests.

          -  A history or laboratory evidence of hepatic impairment and/or disease. Owing to the
             metabolic pathway of BIA 2-093, any degree of hepatic impairment would have had a
             confounding effect on the PK analysis.

          -  Positive test for HIV-1 or HIV-2 Antibodies, Hepatitis B surface antigen and Hepatitis
             C Antibodies.

        HIV positive patients, and patients with Hepatitis B and C, generally have a below average,
        and in some cases a markedly decreased, level of health owing to the nature of the
        respective infections and the natural course of the diseases, both of which are often
        complicated by an array of opportunistic illnesses. Their ill health would have been
        further worsened by the fact that the patients are invarious degrees of renal failure,
        which has its own, often debilitating, complications. If patients with HIV or Hepatitis B
        or C were included in the study, this could have led to statistical confusion when
        assessing the safety and tolerability parameters. This is because events reported by the
        patients, which may be a part of the spectrum of complaints in HIV positive patients and
        Hepatitis B and C patients, would have confounded the safety and tolerability analysis.
        Furthermore, Hepatitis B and C, which may cause an element of hepatic impairment, would
        have confounded the PK analysis due to the metabolic pathway of BIA 2-093. In addition, by
        administering the study medication to these subjects, any adverse events that might have
        occurred would have added to the discomfort of the patient.

          -  A history of any illness that, in the opinion of the Investigator and/or Sponsor,
             might have confounded the results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Farmovs-Parexel</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2014</study_first_submitted>
  <study_first_submitted_qc>October 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2014</study_first_posted>
  <results_first_submitted>November 28, 2014</results_first_submitted>
  <results_first_submitted_qc>December 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 31, 2014</results_first_posted>
  <last_update_submitted>December 18, 2014</last_update_submitted>
  <last_update_submitted_qc>December 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eslicarbazepine acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 Normal Renal Function</title>
          <description>normal renal function (creatinine clearance &gt; 80 mL/min)
BIA 2-093</description>
        </group>
        <group group_id="P2">
          <title>Group 2 Mild Renal Impairment</title>
          <description>mild renal impairment (creatinine clearance 50-80 mL/min)
BIA 2-093</description>
        </group>
        <group group_id="P3">
          <title>Group 3 Moderate Renal Impairment</title>
          <description>moderate renal impairment (creatinine clearance 30-50 mL/min)
BIA 2-093</description>
        </group>
        <group group_id="P4">
          <title>Group 4 Severe Renal Impairment</title>
          <description>severe renal impairment (creatinine clearance &lt;30 mL/min)
BIA 2-093</description>
        </group>
        <group group_id="P5">
          <title>Group 5 End Stage Renal Disease</title>
          <description>end stage renal disease, requiring haemodialysis (ESRD)
BIA 2-093</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 Normal Renal Function</title>
          <description>normal renal function (creatinine clearance &gt; 80 mL/min)
BIA 2-093</description>
        </group>
        <group group_id="B2">
          <title>Group 2 Mild Renal Impairment</title>
          <description>mild renal impairment (creatinine clearance 50-80 mL/min)
BIA 2-093</description>
        </group>
        <group group_id="B3">
          <title>Group 3 Moderate Renal Impairment</title>
          <description>moderate renal impairment (creatinine clearance 30-50 mL/min)
BIA 2-093</description>
        </group>
        <group group_id="B4">
          <title>Group 4 Severe Renal Impairment</title>
          <description>severe renal impairment (creatinine clearance &lt;30 mL/min)
BIA 2-093</description>
        </group>
        <group group_id="B5">
          <title>Group 5 End Stage Renal Disease</title>
          <description>end stage renal disease, requiring haemodialysis (ESRD)
BIA 2-093</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Peak Plasma Concentration</title>
        <description>BIA 2-194; BIA 2-195; Oxcarbazepine are BIA 2-093 metabolites</description>
        <time_frame>pre-dose and 1, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 5, 7, 9, 12, 24, 48, 72 and 96 hours post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Normal Renal Function</title>
            <description>normal renal function (creatinine clearance &gt; 80 mL/min)
BIA 2-093</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Mild Renal Impairment</title>
            <description>mild renal impairment (creatinine clearance 50-80 mL/min)
BIA 2-093</description>
          </group>
          <group group_id="O3">
            <title>Group 3 Moderate Renal Impairment</title>
            <description>moderate renal impairment (creatinine clearance 30-50 mL/min)
BIA 2-093</description>
          </group>
          <group group_id="O4">
            <title>Group 4 Severe Renal Impairment</title>
            <description>severe renal impairment (creatinine clearance &lt;30 mL/min)
BIA 2-093</description>
          </group>
          <group group_id="O5">
            <title>Group 5 End Stage Renal Disease</title>
            <description>end stage renal disease, requiring haemodialysis (ESRD)
BIA 2-093</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Peak Plasma Concentration</title>
          <description>BIA 2-194; BIA 2-195; Oxcarbazepine are BIA 2-093 metabolites</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax (BIA 2-194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14286.790" spread="2988.340"/>
                    <measurement group_id="O2" value="18677.265" spread="4381.474"/>
                    <measurement group_id="O3" value="15055.632" spread="2513.170"/>
                    <measurement group_id="O4" value="14974.79" spread="4313.90"/>
                    <measurement group_id="O5" value="14510.197" spread="2149.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax (BIA 2-195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211.076" spread="61.0200"/>
                    <measurement group_id="O2" value="348.843" spread="69.739"/>
                    <measurement group_id="O3" value="410.828" spread="68.663"/>
                    <measurement group_id="O4" value="465.928" spread="201.988"/>
                    <measurement group_id="O5" value="359.798" spread="119.819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax (Oxcarbazepine)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.339" spread="32.271"/>
                    <measurement group_id="O2" value="172.293" spread="43.431"/>
                    <measurement group_id="O3" value="157.629" spread="35.224"/>
                    <measurement group_id="O4" value="157.955" spread="61.354"/>
                    <measurement group_id="O5" value="208.473" spread="40.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax (hr) - Time at Which Cmax Occurred</title>
        <description>BIA 2-194; BIA 2-195; Oxcarbazepine are BIA 2-093 metabolites
Cmax - maximum observed plasma drug concentration</description>
        <time_frame>pre-dose and 1, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 5, 7, 9, 12, 24, 48, 72 and 96 hours post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Normal Renal Function</title>
            <description>normal renal function (creatinine clearance &gt; 80 mL/min)
BIA 2-093</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Mild Renal Impairment</title>
            <description>mild renal impairment (creatinine clearance 50-80 mL/min)
BIA 2-093</description>
          </group>
          <group group_id="O3">
            <title>Group 3 Moderate Renal Impairment</title>
            <description>moderate renal impairment (creatinine clearance 30-50 mL/min)
BIA 2-093</description>
          </group>
          <group group_id="O4">
            <title>Group 4 Severe Renal Impairment</title>
            <description>severe renal impairment (creatinine clearance &lt;30 mL/min)
BIA 2-093</description>
          </group>
          <group group_id="O5">
            <title>Group 5 End Stage Renal Disease</title>
            <description>end stage renal disease, requiring haemodialysis (ESRD)
BIA 2-093</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (hr) - Time at Which Cmax Occurred</title>
          <description>BIA 2-194; BIA 2-195; Oxcarbazepine are BIA 2-093 metabolites
Cmax - maximum observed plasma drug concentration</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax (BIA 2-194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.121" spread="0.530"/>
                    <measurement group_id="O2" value="1.327" spread="1.004"/>
                    <measurement group_id="O3" value="2.609" spread="2.504"/>
                    <measurement group_id="O4" value="2.680" spread="2.642"/>
                    <measurement group_id="O5" value="1.633" spread="1.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax (BIA 2-195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.008" spread="4.2430"/>
                    <measurement group_id="O2" value="20.185" spread="5.557"/>
                    <measurement group_id="O3" value="26.172" spread="8.485"/>
                    <measurement group_id="O4" value="33.947" spread="12.824"/>
                    <measurement group_id="O5" value="10.773" spread="1.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax (Oxcarbazepine)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.396" spread="0.773"/>
                    <measurement group_id="O2" value="2.581" spread="0.681"/>
                    <measurement group_id="O3" value="3.970" spread="2.397"/>
                    <measurement group_id="O4" value="4.787" spread="3.172"/>
                    <measurement group_id="O5" value="4.260" spread="2.254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-12h) - AUC From Time Zero to 12h</title>
        <description>BIA 2-194; BIA 2-195; Oxcarbazepine are BIA 2-093 metabolites
AUC - area under the plasma concentration versus time curve</description>
        <time_frame>pre-dose and 1, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 5, 7, 9, 12, 24, 48, 72 and 96 hours post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Normal Renal Function</title>
            <description>normal renal function (creatinine clearance &gt; 80 mL/min)
BIA 2-093</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Mild Renal Impairment</title>
            <description>mild renal impairment (creatinine clearance 50-80 mL/min)
BIA 2-093</description>
          </group>
          <group group_id="O3">
            <title>Group 3 Moderate Renal Impairment</title>
            <description>moderate renal impairment (creatinine clearance 30-50 mL/min)
BIA 2-093</description>
          </group>
          <group group_id="O4">
            <title>Group 4 Severe Renal Impairment</title>
            <description>severe renal impairment (creatinine clearance &lt;30 mL/min)
BIA 2-093</description>
          </group>
          <group group_id="O5">
            <title>Group 5 End Stage Renal Disease</title>
            <description>end stage renal disease, requiring haemodialysis (ESRD)
BIA 2-093</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-12h) - AUC From Time Zero to 12h</title>
          <description>BIA 2-194; BIA 2-195; Oxcarbazepine are BIA 2-093 metabolites
AUC - area under the plasma concentration versus time curve</description>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-12h) (BIA 2-194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105275.733" spread="21516.315"/>
                    <measurement group_id="O2" value="150945.034" spread="24049.320"/>
                    <measurement group_id="O3" value="138473.115" spread="19998.869"/>
                    <measurement group_id="O4" value="138262.814" spread="43286.475"/>
                    <measurement group_id="O5" value="134757.936" spread="18609.384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-12h) (BIA 2-195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1522.370" spread="427.4400"/>
                    <measurement group_id="O2" value="2435.245" spread="681.175"/>
                    <measurement group_id="O3" value="2025.731" spread="419.930"/>
                    <measurement group_id="O4" value="2157.860" spread="1092.304"/>
                    <measurement group_id="O5" value="2690.584" spread="731.793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-12h) (Oxcarbazepine)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1218.276" spread="279.550"/>
                    <measurement group_id="O2" value="1388.146" spread="316.857"/>
                    <measurement group_id="O3" value="1460.113" spread="351.507"/>
                    <measurement group_id="O4" value="1496.463" spread="653.928"/>
                    <measurement group_id="O5" value="1832.298" spread="338.896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1 Normal Renal Function</title>
          <description>normal renal function (creatinine clearance &gt; 80 mL/min)
BIA 2-093</description>
        </group>
        <group group_id="E2">
          <title>Group 2 Mild Renal Impairment</title>
          <description>mild renal impairment (creatinine clearance 50-80 mL/min)
BIA 2-093</description>
        </group>
        <group group_id="E3">
          <title>Group 3 Moderate Renal Impairment</title>
          <description>moderate renal impairment (creatinine clearance 30-50 mL/min)
BIA 2-093</description>
        </group>
        <group group_id="E4">
          <title>Group 4 Severe Renal Impairment</title>
          <description>severe renal impairment (creatinine clearance &lt;30 mL/min)
BIA 2-093</description>
        </group>
        <group group_id="E5">
          <title>Group 5 End Stage Renal Disease</title>
          <description>end stage renal disease, requiring haemodialysis (ESRD)
BIA 2-093</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>GENITAL PRURITUS FEMALE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>Bial ‚Äì Portela &amp; C¬™, S.A.</organization>
      <phone>+351 229 866 100</phone>
      <email>jose.rocha@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

